GlyGen Helps Researchers Answer Glycan-related Questions Using Big Data

Technology Networks | November 12, 2019

Of the four building blocks of life – proteins, lipids, nucleic acids and glycans (carbohydrates) – the latter have received the least attention from researchers. This may be about to change as a new project, GlyGen, launches to help researchers answer glycan-related questions using big data. GlyGen is the first project that integrates and harmonises glycan data from multiple international data sources, making it much faster and simpler for researchers to explore the data and perform unique searches. The portal currently contains glycan data for three species: human, mouse and rat. More organisms will be added in the near future. GlyGen is a project coordinated by George Washington University and the University of Georgia, in collaboration with EMBL-EBI’s Protein Function Development team, which contributed its expertise in data science integration. The project is funded by the National Institutes of Health. “Before the launch of GlyGen, researchers had to dig through multiple resources to find information on their glycan of interest,” explains Maria Martin, Team Leader at EMBL-EBI. “Now, they can perform a unique search that simultaneously checks multiple resources. In addition, GlyGen also pulls proteomics and genomics information, offering a truly comprehensive picture for researchers.”

Spotlight

Many  biopharma companies, in pursuit of a balanced portfolio and a robust development pipeline, are increasingly sourcing research and development (R&D) assets externally. In fact, the proportion of biopharma revenue generated by drugs sourced from other companies rose from 41 percent in 2005 to 50 percent in 2014.

Spotlight

Many  biopharma companies, in pursuit of a balanced portfolio and a robust development pipeline, are increasingly sourcing research and development (R&D) assets externally. In fact, the proportion of biopharma revenue generated by drugs sourced from other companies rose from 41 percent in 2005 to 50 percent in 2014.

Related News

MEDICAL

CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays

CellCarta | May 23, 2022

CellCarta, a leading global provider of precision medicine laboratory services, announced today the acquisition of the commercial rights to the antibody panels and assays from Precision Assays, a leader in next-generation targeted proteomics testing solutions. A spin-off from Fred Hutchinson Cancer Center ("Fred Hutch"), Precision Assays develops and deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its pharmaceutical and biotech industry clients. The acquisition from Precision Assays of its large spectrum of targeted mass spectrometry assays characterized according to the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) Tier 2 guidelines greatly expands CellCarta's capabilities in off-the-shelf multiplex protein quantification offerings ready for deployment in immuno-oncology clinical and pre-clinical studies. Precision Assays' large portfolio of robust assays characterized according to CPTAC guidelines and its established proof of concept data will enable CellCarta to confidently support its clients' exploratory studies and therapeutic development strategies, offering them key solutions to address important clinical challenges and move their immuno-oncology programs forward. Given CellCarta's expertise in protein quantitation, these immuno-MRM panels can further be validated to support secondary and primary clinical endpoints." Lorella Di Donato, Chief Operating Officer of CellCarta, Immunology and Proteomics Divisions. Based on technology licensed from Fred Hutch, Precision Assays' platform is uniquely positioned to fully capture the unique advantages of multiplex protein quantification using targeted mass spectrometry. Founder Dr. Amanda Paulovich, a professor in the Clinical Research Division at Fred Hutch who holds the Aven Foundation Endowed Chair, is an internationally recognized pioneer in targeted mass spectrometry and a clinically trained oncologist. Dr. Paulovich has set best-in-class standards to support precision medicine studies in cancer-specific protein expression analysis in a variety of matrices from FFPE cancer tissue biopsies to clinical serum-based samples. Precision Assays is one of the few CROs to offer large and immuno-oncology relevant multiplex off-the-shelf panels and is at the forefront of targeted-mass spec proteomics-based research. As a global CRO with expertise in targeted mass spectrometry and specializing in biomarker testing to support precision medicine, CellCarta is an ideal partner to deploy and industrialize our platform to support discovery, translational and clinical research, especially in precision medicine and immuno-oncology." Paulovich About CellCarta CellCarta is a leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. The company operates globally with 11 facilities located in Canada, USA, Belgium, Australia, and China.

Read More

CELL AND GENE THERAPY

Sysmex and ThinkCyte Have Entered into An Agreement for Joint Development and Capital Alliance

Sysmex Corporation | May 17, 2021

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. Meanwhile, telehealth, AI-powered medical imaging analysis, and automated testing of robots are all gaining traction in the healthcare industry. Sysmex has been acquiring technologies for studying cells, genes, and proteins with high accuracy and sensitivity on a proactive basis. A cell analysis platform is one of the technologies that has been used in a variety of Sysmex products. In this field, Sysmex's current emphasis is on developing technologies that specifically analyze cells using different types of information such as cell function and responsiveness, as well as seeking faster cell analysis. ThinkCyte has "Ghost Cytometry technology," which analyses morphological information of cells in a quick and simple process, while the information gathered by this technology is much richer than what can be collected using conventional flow cytometry (FCM) technique. This technology, in addition to counting and analyzing cells based on their basic morphological features, helps users to identify each cell based on its specific morphological details in terms of its characteristics and functions. This high-resolution analysis will allow for highly accurate clinical condition determination using body fluids such as blood, improve precision in a wide variety of cell-based diagnoses, and contribute to more personalized healthcare. On March 31, 2021, Sysmex and ThinkCyte signed a memorandum of understanding to begin full-fledged joint development of the novel AI-based cell analysis technology as a result of ongoing collaborative research between the two companies to increase the viability of applying Ghost Cytometry technology to diagnostic techniques of high clinical value. In addition, on May 1, 2021, the two companies agreed to collaborate on joint development, with the aim of commercializing cell analyzers and testing techniques based on Ghost Cytometry technology for cell analysis (including research) in the field of in-vitro diagnostics (IVD). Meanwhile, on May 11, 2021, Sysmex agreed to make an equity investment in ThinkCyte, which will enable the two companies to enhance their strong partnership. Sysmex and ThinkCyte have formed an alliance to develop novel cell analysis technology and research techniques by combining Sysmex's IVD capabilities with ThinkCyte's proprietary Ghost Cytometry technology, thereby contributing to the advancement and evolution of healthcare around the world. About Sysmex Corporation Sysmex works to contribute to the development of healthcare and people's healthy lives in accordance with its goal of "shaping the advancement of healthcare," as described in the Sysmex Group's corporate ideology, the "Sysmex Way." Sysmex performs integrated R&D, manufacturing, and sales, as well as providing support services for its in vitro blood, urine, and other bodily fluids testing instruments, reagents, and software. Sysmex's products are sold to medical institutions in over 190 countries and regions around the world. Sysmex has been expanding its business in the life science domain in recent years, using proprietary technologies to develop new testing and diagnostic value, provide healthcare personalized to individual patients, and help patients minimize burdens and improve quality of life.

Read More

CELL AND GENE THERAPY

Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

Moderna | December 14, 2021

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the agreement. “I would like to thank the Australian and Victorian Governments for their collaboration and partnership. We are committed to global public health and while we are still responding to this pandemic, we also want to ensure we and society learn from it. As Moderna expands internationally, we are pleased to bring local mRNA manufacturing to Australia. We believe that this sustainable national business model will have global impact and implications.” Stéphane Bancel, Chief Executive Officer of Moderna Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state-of-the-art manufacturing facility for the production of mRNA vaccines with the collaboration of the Commonwealth and Victorian Governments. The collaboration aims to provide Australians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus and potential other vaccines, pending licensure. Moderna expects that up to 100 million vaccine doses could be produced in Australia each year. The facility is intended to also be activated on an urgent basis to support Australia with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model. “We are excited to expand our presence and continue our long-term collaboration with the Australian and Victorian Governments,” said Michael Azrak, Moderna’s General Manager of Australia. “We look forward to completing the necessary discussions and starting work to develop onshore mRNA manufacturing capability here in Australia.” The agreement was announced today in Victoria by the Hon. Scott Morrison, MP Prime Minister of Australia. About Moderna In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic. Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years.

Read More